Aethlon Medical Announces Issuance of Hemopurifier® Patents for the Treatment of Long COVID and COVID-19-associated Coagulopathy (CAC)

Stock Information for NCS Multistage Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About NCS Multistage Holdings Inc.

Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 12, 2025
Biotech and Medical Tech Stocks Report Breakthrough Clinical Trial Updates
Aethlon Medical's Hemopurifier® shows Changes in Extracellular Vesicles, Extracellular MicroRNAs, and T Cell Numbers in Australian Oncology Clinical Trial
Aethlon Medical Announces Pricing of $4.5 Million Public Offering
Innovation and IP in Medtech Stocks - How Patents Build Leaders
Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2025, and Provides Corporate Update
Aethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 13, 2025
Aethlon Medical, Inc. Announces Positive Data Safety Monitoring Board Review and Recommendation to Advance to Next Clinical Trial Cohort

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.